
Ahead of Hong Kong IPO, China drug maker Hengrui touts partnership with US giant Merck
Jiangsu Hengrui Pharmaceuticals, a leading Chinese developer of novel drugs that recently received approval to go public in Hong Kong, is likely to see an acceleration in growth as its research and development (R&D) pipeline bears fruit, analysts said. …